Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.56 |
| ▸ | HTR1A | P08908 | 9/20 | 0.56 |
| ▸ | DRD2 | P14416 | 7/20 | 0.56 |
| ▸ | HTR7 | P34969 | 6/20 | 0.56 |
| ▸ | HTR6 | P50406 | 6/20 | 0.56 |
| ▸ | HTR2A | P28223 | 5/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8820411 | 0.91 | SLC6A4 (0.60) | SLC6A4HTR1ADRD2HTR7HTR6 | |
| Trifluoromethanesulfonic Acid SCHEMBL7870840 | 0.90 | SLC6A4 (0.50) | SLC6A4HTR1ADRD2HTR7HTR6 | |
| SCHEMBL9031074 | 0.83 | HTR1A (0.47) | SLC6A4HTR1ADRD2HTR7HTR6 | |
| SCHEMBL7482980 | 0.82 | HTR1D (0.50) | SLC6A4HTR1ADRD2HTR7HTR6 | |
| Trifluoromethanesulfonic Acid SCHEMBL7867294 | 0.82 | DRD2 (0.52) | SLC6A4HTR1ADRD2HTR7HTR6 | |
| SCHEMBL18474133 | 0.81 | MTNR1A (0.49) | SLC6A4HTR1AHTR7HTR6HTR2A | |
| SCHEMBL7485048 | 0.80 | HTR1D (0.51) | SLC6A4HTR1ADRD2HTR7HTR6 | |
| SCHEMBL8880695 | 0.80 | SLC6A4 (0.67) | SLC6A4HTR1ADRD2HTR7HTR6 | |
| SCHEMBL8876508 | 0.80 | HTR6 (0.55) | SLC6A4HTR1AHTR6HTR2A | |
| SCHEMBL7489644 | 0.79 | HTR1D (0.53) | SLC6A4HTR1ADRD2HTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997047302-A1 | INHIBITION OF SEROTONIN REUPTAKE | ELI LILLY AND COMPANY (US) | 1997-12-18 | — | — | WO | disclosed |